Source link : https://www.newshealth.biz/health-news/lack-of-clinical-benefit-of-andexanet-flummoxes-fda-panel/
FDA advisors pushed for nuance in discussing whether andexanet alfa (Andexxa) should gain full approval, citing uncertainties about which dose and in which patients it could be best used to stop bleeding. Members of the Cellular, Tissue, and Gene Therapies Advisory Committee agreed on Thursday that andexanet has a demonstrated ability to control hematoma volume […]
Author : News Health
Publish date : 2024-11-21 22:32:02
Copyright for syndicated content belongs to the linked Source.
Categories